On the other hand, these biomarkers, principally the reduction of p-tau/t-tau ratio and Abeta42, were correlated with both ALS progression rate and the time elapsed from diagnosis to death. The gene discussed is MAPT; the disease is amyotrophic lateral sclerosis.